Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 2/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 4/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | PTPRB | P23467 | 2/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3222983 | 0.88 | ATM (0.39) | ITGA4ITGB7ATMAPPCTSS | |
| SCHEMBL2617430 | 0.88 | ITGA4 (0.39) | ITGA4ITGB7ATMAPPCTSS | |
| SCHEMBL10215115 | 0.88 | ITGA4 (0.39) | ITGA4ITGB7ATMAPPCTSS | |
| SCHEMBL13162785 | 0.86 | MEN1 (0.37) | ITGA4ITGB7ATMCTSSCTSK | |
| SCHEMBL2103666 | 0.86 | MEN1 (0.37) | ITGA4ITGB7ATMCTSSCTSK | |
| SCHEMBL2631416 | 0.83 | ATM (0.38) | ITGA4ITGB7ATMAPPCTSS | |
| SCHEMBL4794108 | 0.82 | ITGA4 (0.34) | ITGA4ITGB7ATMAPPCTSS | |
| SCHEMBL2617422 | 0.82 | ATM (0.38) | ITGA4ITGB7ATMAPPCTSS | |
| SCHEMBL2617428 | 0.78 | ATM (0.43) | ITGA4ITGB7ATMAPPCTSS | |
| SCHEMBL10215114 | 0.78 | ATM (0.43) | ITGA4ITGB7ATMAPPCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163919-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-7504413-B2 | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases | CYTOKINETICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | ITGA4 4137/4885ITGB7 4209/4885ATM 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.